Malignant Triton Tumor of the Distal Femur: A Case Report and Review of the Literature.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2024-11-01 DOI:10.21873/invivo.13796

Yoshitaka Ban, Naoto Oebisu, Hana Yao, Naoki Takada, Manabu Hoshi, Hiroaki Nakamura, Kenichi Kohashi

{"title":"Malignant Triton Tumor of the Distal Femur: A Case Report and Review of the Literature.","authors":"Yoshitaka Ban, Naoto Oebisu, Hana Yao, Naoki Takada, Manabu Hoshi, Hiroaki Nakamura, Kenichi Kohashi","doi":"10.21873/invivo.13796","DOIUrl":null,"url":null,"abstract":"Background/aim: Malignant triton tumor (MTT) is a rare, highly aggressive malignant nerve sheath tumor with rhabdomyoblastic differentiation. The overall 5-year survival rate is extremely low, and no standardized treatment exists. We report a case of MTT in the distal femur that was treated with surgery and chemotherapy.Case report: A 16-year-old male was referred to our hospital due to severe pain during physical activity and difficulty in walking. He showed no café-au-lait spots and no family history of Neurofibromatosis-1. He underwent an incisional biopsy and was diagnosed with MTT of the distal femur. After administering preoperative chemotherapy using adriamycin, ifosfamide, and cisplatin, wide resection surgery was performed for MTT. Subsequently, postoperative chemotherapy using methotrexate, in addition to the agents mentioned above, was administered. One and a half years after the surgery, he can walk without pain, and there are no signs of local recurrence or metastasis.Conclusion: The combined modality treatment, integrating chemotherapy and surgery, has successfully prevented local recurrence and accomplished favorable outcomes without lung metastasis.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"3112-3116"},"PeriodicalIF":1.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535929/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13796","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Malignant triton tumor (MTT) is a rare, highly aggressive malignant nerve sheath tumor with rhabdomyoblastic differentiation. The overall 5-year survival rate is extremely low, and no standardized treatment exists. We report a case of MTT in the distal femur that was treated with surgery and chemotherapy.

Case report: A 16-year-old male was referred to our hospital due to severe pain during physical activity and difficulty in walking. He showed no café-au-lait spots and no family history of Neurofibromatosis-1. He underwent an incisional biopsy and was diagnosed with MTT of the distal femur. After administering preoperative chemotherapy using adriamycin, ifosfamide, and cisplatin, wide resection surgery was performed for MTT. Subsequently, postoperative chemotherapy using methotrexate, in addition to the agents mentioned above, was administered. One and a half years after the surgery, he can walk without pain, and there are no signs of local recurrence or metastasis.

Conclusion: The combined modality treatment, integrating chemotherapy and surgery, has successfully prevented local recurrence and accomplished favorable outcomes without lung metastasis.

查看原文本刊更多论文

股骨远端恶性天疱疮：病例报告与文献综述

背景/目的：恶性三尖杉瘤（MTT）是一种罕见的高度侵袭性恶性神经鞘瘤，具有横纹肌母细胞分化。其总体 5 年生存率极低，且没有标准化的治疗方法。我们报告了一例股骨远端 MTT 病例，患者接受了手术和化疗治疗：病例报告：一名 16 岁的男性因体力活动时剧烈疼痛和行走困难而转诊至我院。他身上没有咖啡色斑块，也没有神经纤维瘤病-1家族史。他接受了切口活检，被诊断为股骨远端 MTT。术前使用阿霉素、伊福酰胺和顺铂进行化疗后，对MTT进行了广泛切除手术。随后，除上述药物外，还使用了甲氨蝶呤进行术后化疗。术后一年半，他可以无痛行走，也没有局部复发或转移的迹象：结论：化疗与手术相结合的综合治疗方式成功地防止了局部复发，并取得了良好的疗效，且未出现肺转移。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.